

[DISCUSSION DRAFT]

115TH CONGRESS
2^D SESSION

H. R. _____

To amend title XIX of the Social Security Act to require as a condition of receipt of full Federal medical assistance percentage under Medicaid that State Medicaid plans have in place certain drug utilization review activities.

IN THE HOUSE OF REPRESENTATIVES

M____ introduced the following bill; which was referred to the
Committee on _____

A BILL

To amend title XIX of the Social Security Act to require as a condition of receipt of full Federal medical assistance percentage under Medicaid that State Medicaid plans have in place certain drug utilization review activities.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicaid Drug Review,
5 Utilization, Good Governance Improvement Act” or the
6 “Medicaid DRUG Improvement Act”.

1 **SEC. 2. MEDICAID DRUG UTILIZATION REVIEW.**

2 (a) STATE PLAN REQUIREMENT.—Section 1902(a)
3 of the Social Security Act (42 U.S.C. 1396a(a)) is amend-
4 ed—

5 (1) in paragraph (82), at the end, by striking
6 “and”;

7 (2) in paragraph (83), at the end, by striking
8 the period and inserting “; and”; and

9 (3) by inserting after paragraph (83) the fol-
10 lowing new paragraph:

11 “(84) provide that the State is in compliance
12 with the drug review and utilization requirements
13 under subsection (nn)(1).”.

14 (b) DRUG REVIEW AND UTILIZATION REQUIRE-
15 MENTS.—Section 1902 of the Social Security Act (42
16 U.S.C. 1396a) is amended by adding at the end the fol-
17 lowing new subsection:

18 “(nn) DRUG REVIEW AND UTILIZATION REQUIRE-
19 MENTS.—

20 “(1) IN GENERAL.—For purposes of subsection
21 (a)(84), the drug review and utilization requirements
22 under this subsection are, beginning October 1,
23 2019, the following:

24 “(A) CLAIMS REVIEW LIMITATIONS.—

25 “(i) IN GENERAL.—The State has in
26 place—

1 “(I) limitations (as specified by
2 the State) on coverage of refills for
3 opioids and a claims review automated
4 process (as designed and implemented
5 by the State) that indicates when an
6 individual enrolled under the State
7 plan (or under a waiver of the State
8 plan) is prescribed a refill of opioids
9 in excess of such limitation, requiring
10 the denial of coverage under the State
11 plan (or waiver) of such refill;

12 “(II) limitations (as specified by
13 the State) on the daily milligrams of
14 buprenorphine **【**and on the maximum
15 daily morphine equivalent**】** that can
16 be prescribed to an individual enrolled
17 under the State plan (or under a
18 waiver of the State plan) and a claims
19 review automated process (as designed
20 and implemented by the State) that
21 indicates when an individual enrolled
22 under the plan (or waiver) is pre-
23 scribed buprenorphine **【**or the mor-
24 phine equivalent**】** in excess of such

1 limitation, requiring the denial of cov-
2 erage under the plan (or waiver); and

3 “(III) a claims review automated
4 process (as designed and implemented
5 by the State) that monitors when an
6 individual enrolled under the State
7 plan (or under a waiver of the State
8 plan) is concurrently prescribed
9 opioids and—

10 “(aa) benzodiazepines;

11 “(bb) antipsychotics, or

12 “(cc) drugs for the treat-
13 ment of human immunodeficiency
14 virus (HIV).

15 “(ii) MANAGED CARE ENTITIES.—The
16 State requires each managed care entity
17 (as defined in section 1932(a)(1)(B)) with
18 respect to which the State has a contract
19 under section 1903(m) or under section
20 1905(t)(3) to have in place, with respect to
21 individuals who are eligible for medical as-
22 sistance under the State plan (or under a
23 waiver of the State plan) and who are en-
24 rolled with the entity, the limitations de-
25 scribed in subclauses (I) and (II) of clause

1 (i) and a claims review automated process
2 described in subclause (III) of such clause.

3 “(B) FORMULARY REQUIREMENT.—The
4 State requires at least one buprenorphine/
5 naloxone combination drug on the formulary of
6 the State plan (or waiver of the State plan).

7 “(C) PROGRAM TO MONITOR
8 ANTIPSYCHOTIC MEDICATIONS BY CHILDREN.—
9 The State has in place a program (as designed
10 and implemented by the State) to monitor and
11 manage the appropriate use of antipsychotic
12 medications by children enrolled under the
13 State plan (or under a waiver of the State plan)
14 and submits annually to the Secretary such in-
15 formation as the Secretary may require on ac-
16 tivities carried out under such program for indi-
17 viduals not more than the age of 18 years gen-
18 erally and children in foster care specifically.

19 “(D) FRAUD AND ABUSE IDENTIFICA-
20 TION.—The State has in place a process (as de-
21 signed and implemented by the State) that
22 identifies potential fraud or abuse of controlled
23 substances by individuals enrolled under the
24 State plan (or under a waiver of the State
25 plan), health care providers prescribing drugs

1 to individuals so enrolled, and pharmacies dis-
2 pensing drugs to individuals so enrolled.

3 “(E) REPORTS.—The State submits to the
4 Secretary a report on information on the limita-
5 tions, requirement, program, and processes ap-
6 plied by the State under subparagraphs (A)
7 through (D) in accordance with such manner
8 and time as specified by the Secretary.

9 “(2) ANNUAL REPORT BY SECRETARY.—For
10 each fiscal year beginning with fiscal year 2020, the
11 Secretary shall submit to Congress a report con-
12 taining information on the most recent reports sub-
13 mitted by States under paragraph (1)(E).”.

14 (c) MANAGED CARE ENTITIES.—Section 1932 of the
15 Social Security Act (42 U.S.C. 1396u–2) is amended by
16 adding at the end the following new subsection:

17 “(i) DRUG UTILIZATION REVIEW ACTIVITIES AND
18 REQUIREMENTS.—Beginning not later than October 1,
19 2019, each contract under a State plan with a managed
20 care entity under section 1903(m) or under section
21 1905(t)(3) shall provide that the entity is in compliance
22 with the applicable provisions of section 438.3(s)(2) of
23 title 42 of the Code of Federal Regulations, section
24 483.3(s)(4) of such title, and section 483.3(s)(5) of such
25 title, or any successor regulation to such provisions.”.

1 (d) REDUCTION IN FMAP FOR NONCOMPLIANCE.—
2 Section 1903 of the Social Security Act (42 U.S.C. 1396b)
3 is amended by adding at the end the following new sub-
4 section:

5 “(aa) REDUCTION FOR FAILURE TO COMPLY WITH
6 DRUG REVIEW AND UTILIZATION REQUIREMENTS.—For
7 any fiscal year beginning after fiscal year 2019, in the
8 case that a State does not comply with the drug review
9 and utilization requirements under section 1902(n) with
10 respect to each calendar quarter in such year, the Federal
11 medical assistance percentage shall be reduced by 0.025
12 percentage point with respect to amounts expended for
13 items and services furnished in calendar quarters the sub-
14 sequent fiscal year.”.